🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — April 14, 2026

Overnight SEC filings reveal a surge in M&A activity, particularly in healthcare (Avanos acquisition at 72% premium, Kezar tender at $6.955/share + CVR, Day One tender at $21.50/share) and energy transition (XCF/DevvStream/Southern merger targeting $1B revenue/$100M EBITDA), signaling sector consolidation amid growth ambitions. Financial results show mixed trends: 4/10 reporting companies posted YoY net income growth (e.g., Unity Bancorp +23.2%, Wells Fargo +7%), but QoQ declines prevalent (Unity -7.7%, Wells -2%) with margin pressures in semis/manufacturing (AstroNova gross profit -7.4% YoY, Chipmos margins to 10.8%, SemiLEDs revenue -90% YoY). Small caps face headwinds (Northann revenue -11.4% YoY, operating loss -84.2% of revenue; Alphega net loss +92% YoY; Hydrofarm forbearance on $125M loan), while biopharma shines (Travere FDA approval for FILSPARI, 46% proteinuria reduction). 13F filings (10/50) indicate institutional stability with no position changes in most (e.g., SeaTown, Value Investment flat QoQ). Capital returns strong (Unity dividend +7% to $0.16/share, Wells $4B buyback), but risks from settlements (Westlake $67M), restatements (Nature's Miracle), and control weaknesses (American Battery). Portfolio-level: Healthcare/energy bullish, small caps/banks mixed; watch H2 2026 closings and Q2 earnings for catalysts.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Technology Sector SEC Filings — April 13, 2026

Across 14 filings in the S&P 500 Technology stream, institutional 13F-HRs reveal overwhelming conviction in core tech leaders, with NVDA topping holdings in 4/5 reports (total ~$750M+ exposure), AAPL/MSFT/AMZN following closely in multi-billion portfolios, signaling sustained AI/semi/mega-cap strength amid Q1 2026 positioning. Palo Alto Networks (PANW) stands out with a bullish long-term lease extension for 290k sq ft to 2040 ($13M-$16M annual rent), underscoring cybersecurity expansion. Non-tech filings show mixed trends: Pineapple Financial bolstered balance sheet with $72M funding despite $23M crypto loss (-5.5% rev YoY), Jewett-Cameron posted +4.7-16.4% sales growth but -83.8% gross profit H1 YoY driving $5.2M loss. Proxy materials for Dime/Genco neutral, Pershing Square advances PSUS IPO and $2.1B Q2 2026 M&A for AUM growth, while Replimune faces 2nd FDA CRL setback. Portfolio-level: Revenue growth in 2/4 10-Qs but margin compression/losses dominate small caps; tech signals bullish via institutions/PANW.

5 high priority 9 medium 14 total filings
· daily

Nasdaq 100 Stocks SEC Filings — April 13, 2026

Across 13 SEC filings from NASDAQ-100 constituents and related entities, key themes include divergent financial performances with revenue growth in AI and trading sectors offset by sharp losses from crypto impairments and operational declines; biotech faces regulatory hurdles while proxies signal active governance seasons for banks and shipping. Period-over-period trends show 2/5 financial reporters with revenue growth (AITX +26% YoY, Jewett-Cameron +16.4% YoY Q3) but widespread margin compression (Jewett gross profit -83.8% YoY half-year, Pineapple expenses +820% YoY due to $23M crypto loss) and net losses expanding (Jewett net loss $5.2M half-year vs prior, Pineapple $25.9M). Institutional 13F filings reveal heavy concentration in megacap tech (NVDA, AAPL, MSFT topping portfolios totaling billions), indicating sustained conviction amid volatility. Positive catalysts include board strengthening at CMC and balance sheet fortification at Pineapple via $52M+ financing; risks dominate in crypto (Intchains negative cash flows, no dividends) and biotech (Replimune second FDA CRL). Portfolio-level implications favor selective longs in AI/growth stories and caution on speculative crypto/biotech exposures ahead of proxy votes and earnings.

5 high priority 8 medium 13 total filings
· daily

S&P 500 Financials Sector SEC Filings — April 13, 2026

Across 50 filings from the USA S&P 500 Financials intelligence stream (broadly including banks, insurers, asset managers, and adjacent sectors), dominant themes include robust M&A activity (e.g., Somnigroup-LEG $2.5B all-stock deal, Clear Channel $2.43/share buyout), IPO preparations (Alamar Biosciences, Kailera Therapeutics), and mixed financial results with revenue growth averaging ~60% YoY in reporting small caps (e.g., Alamar 195%, OriginClear 55%) offset by persistent margin compression (avg -200bps in 4/7 detailed firms) and net losses. Biotech/healthcare filings show positive trial catalysts (IDEAYA PFS HR 0.42, Spyre RHI -9.2 pts), while operational disruptions like contract losses (Ameriguard 58% revenue hit) and regulatory setbacks (Replimune 2nd CRL) temper optimism. Capital allocation leans shareholder-friendly with dividend hikes (American States +8.3%) and buybacks (News Corp $1B program), but Nasdaq compliance risks (Sow Good equity < $2.5M) and leadership changes signal caution. Portfolio-level trends reveal 8/15 revenue reporters growing >20% YoY, yet 5/7 margins declining amid SG&A surges; forward catalysts cluster in H2 2026 (FDA NDAs, Phase 3 readouts, merger closes). Overall, actionable alpha lies in M&A arbitrage and biotech turnarounds, with financials showing stable but unexciting EPS growth (e.g., ChoiceOne proxy neutral).

27 high priority 23 medium 50 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — April 13, 2026

Across the 50 filings in the USA S&P 500 Consumer Staples intelligence stream, direct staples exposure is limited to Conagra Brands (CEO transition) and Coca-Cola Europacific Partners (share repurchases), amid a broader mix of proxy statements, financial reports, and M&A updates; overarching themes include active proxy season with 15+ DEF/DEFA14A filings seeking director elections and compensation approvals, and resilient revenue growth in small-caps averaging +77% YoY where reported (Envirotech +218%, OriginClear +55%, Elite Express +16%). Period-over-period trends show 6/12 financial filings with YoY revenue gains but mixed margins (e.g., AITX gross margins +1000bps to 71%, Kopin cost/revenue 84.2% stable), offset by cash drains (Elite Express cash -95% QoQ to $68K) and losses (Edgemode net loss +1450% to $24.6M). Capital allocation leans shareholder-friendly with dividends up (Farmer Mac +7% YoY quarterly, KKR FS Income $0.225/share monthly), buybacks (Teleflex $1B from $1.8B divestiture proceeds), and repurchases (CCEP 273K shares). Forward-looking catalysts cluster in H2 2026 (Teleflex divest closes, Perella Weinberg acquisition) and Q2 2026 (Diamond Hill merger), with positive sentiment in 12/50 filings driven by M&A and leadership stability. Portfolio-level patterns flag staples-adjacent strength in food/agri (Conagra $12B sales, Farmer Mac 116% ROE) versus risks in delisting threats and lawsuits, implying selective buying opportunities pre-catalysts.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Industrials Sector SEC Filings — April 13, 2026

Proxy season dominates the 50 filings with over 20 DEF 14A/DEFA14A announcements for annual meetings clustered in May-June 2026, focusing on director elections, auditor ratifications, and compensation votes, mostly neutral sentiment but highlighting governance strengths like 100% board independence at Farmer Mac. Financial disclosures reveal mixed trends: Bancorp assets +8.0% YoY to $9.4B, net income +4.6% to $228M, ROE 29% (up from 27%); Farmer Mac record 116% ROE, book value $112.77 (+YoY), dividend +7%; contrasted by TOFUTTI sales -11.8% YoY to $7.8M, op loss +27.5%; Edgemode net loss ballooned to $24.6M from $1.6M, liabilities x4.2 to $20.1M. Positive catalysts include Leggett & Platt $2.5B all-stock acquisition (0.1455x exchange ratio), IDEAYA Phase 2/3 PFS 6.9mo vs 3.1mo (HR 0.42), Diamondback Q1 hedged oil $72.53/bbl with $133M derivative gain, AITX FY26 rev +26% to $7.75M/margins +10pts to 71%. 13F-HR filings (12 total) show institutional heavy tilt to tech (Apple/MSFT/NVDA top across $10B+ AUM), minimal Industrials exposure. Industrials-specific: Caterpillar director nominee Aug 1, Patterson-UTI LTIP expansion +28.9M shares (overhang to 11.3%), Genco Shipping proxy solicitation. Overall neutral-to-mixed sentiment (avg materiality 5.8/10), with capital allocation favoring dividends/equity plans amid limited M&A/insider data.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Energy Sector SEC Filings — April 13, 2026

Across 7 filings in the S&P 500 Energy intelligence stream, 5 neutral 13F-HR reports from advisors (Whalen Wealth, Chesley Taft, Global X Japan, MKD Wealth, John Brooker) reveal snapshot holdings as of March 31, 2026, heavily weighted toward tech giants (Apple, NVIDIA, Broadcom) and ETFs with no period-over-period comparisons, changes, or energy-specific allocations disclosed, signaling institutional caution or underweight in energy. Key positive: Marathon Petroleum (MPC) secured a new $5B revolving credit agreement on April 7, 2026, with favorable tiered pricing (e.g., Level I Term SOFR Spread 1.000%) and standard covenants, enhancing liquidity without issues (positive sentiment, materiality 9/10). Critical negative: Southern Copper (SCCO) announced unexpected CEO/President Oscar Gonzalez Rocha passing on April 7, 2026, with successor planned soon (negative sentiment, materiality 9/10). No YoY/QoQ trends, insider trades, capital allocation shifts, M&A, or scheduled events across filings; portfolio-level pattern shows diversified managers favoring tech/ETFs (e.g., Apple top holding in 5/5 13Fs) over energy, implying sector underperformance relative to broader market.

1 high priority 6 medium 7 total filings
· daily

US Material Events SEC 8-K Filings — April 13, 2026

Across the 50 8-K filings from April 13, 2026, dominant themes include aggressive M&A activity (e.g., Somnigroup's $2.5B acquisition of Leggett & Platt, Investcorp AI's $220M deal), widespread leadership transitions (18 appointments/resignations/retirements, including C-suite at Conagra, FedEx, NET Power), and robust financing events (credit facilities totaling >$9B across Marathon Petroleum, MPLX, AdaptHealth; equity raises like Angel Studios' $30M). Positive sentiment in 65% of filings reflects growth catalysts like AI/tech integrations (WEBTOON, Golkor, VisionWave) and expansions, while mixed/negative cases highlight distress (Nasdaq delistings for ClearOne/Sow Good, contract loss at Ameriguard eroding 58% 2026 revenue). No uniform PoP financial trends due to event focus, but enriched data shows capital allocation tilting to debt/equity raises (e.g., 30.6% increase in Xenon's inducement shares) over buybacks/dividends; insider conviction neutral with no major buys/sells reported. Portfolio implications: overweight M&A plays for synergies (avg $500M+ deals), avoid small-cap compliance risks; sector rotation to AI/energy (Bloom/Oracle warrant for AI data centers). Critical watch: Q2 2026 catalysts like merger closings, Nasdaq plans.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — April 13, 2026

Across 50 SEC filings from April 13, 2026, primarily involving non-DJ30 names despite the stream focus, dominant themes include a surge in proxy statements (DEF 14A/DEFA14A) for May 2026 annual meetings (e.g., Kyverna, First Busey, Dime Community), board changes/retirements (Independent Bank, 5E Advanced Materials, Caterpillar), and SPAC/M&A activity (Investcorp AI $220M deal, Spring Valley fusion tech, Brag House merger approval). Period-over-period trends show pockets of strength like Envirotech sales +218% YoY to $5.9M, Civeo Australian revenue $460M (72% total, EBITDA +10% YoY), Bancorp assets +8% to $9.4B/net income +4.6% to $228M/ROE +2pp to 29%, offset by weaknesses such as Pineapple revenue -5.5% YoY to $1.4M/huge $26M net loss from crypto, Intchains ongoing losses/negative cash flows. Capital allocation highlights include Franklin Financial dividend +3% YoY to $0.34/share, Civeo $54M buyback (17% shares), Diamondback debt tenders; forward-looking catalysts cluster in biotech (Kyverna BLA H1 2026) and fusion/SPACs. Mixed sentiment prevails with Nasdaq compliance strains (Veea transfer to Capital Market), but positive M&A momentum and derivative gains (Diamondback $133M Q1) signal selective opportunities amid governance churn.

22 high priority 28 medium 50 total filings
· daily

US SEC Filings Daily Market Digest — April 13, 2026

Across 50 SEC filings for April 13, 2026, dominant themes include a biotech surge with positive Phase 2/3 trial data (IDEAYA, Spyre, Allogene) signaling upcoming NDAs and catalysts, robust M&A activity (Somnigroup/LEG $2.5B all-stock deal, Clear Channel $2.43/share buyout, Comstock acquisition), and mixed small-cap financials showing revenue acceleration (Alamar 195% YoY to $74.2M, EACO 17.7% YoY Q2 to $117.8M, OriginClear 55% YoY) but persistent net losses and margin compression (Digital Ally gross margin 10% vs 23% YoY, ALT5 41% vs 48%). Period-over-period trends reveal 6/12 earnings reporters with double-digit revenue growth averaging +80% YoY, but 7/12 with operating losses widening due to SG&A surges (ALT5 +163%). Capital allocation leans shareholder-friendly in utilities (AWR 8.3% dividend hike, 71st year), while Nasdaq delisting risks (Sow Good equity <$2.5M) and FDA setbacks (Replimune CRL) flag vulnerabilities. 13F filings highlight institutional tech concentration (E Fund Apple $182M top, Czech National Bank Apple $1B). Portfolio implications: Biotech overweight for H2 2026 catalysts, selective M&A arbitrage, avoid distressed small caps.

27 high priority 23 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — April 13, 2026

Across 50 filings primarily from diverse sectors but focused on S&P 500 Consumer Discretionary context, proxy statements (DEF 14A/DEFA14A) dominate with 12+ companies gearing up for May-June 2026 annual meetings, signaling governance focus amid mixed financials. Period-over-period trends reveal revenue growth in 7/15 financial reporters (e.g., Marti +109% YoY to $39M, Arts-Way +29% YoY sales, AITX +26% FY2026 prelim), but declines in 5 (e.g., New Fortress -36% YoY revenues, TOFUTTI -11.8% sales), with margin improvements in 4 (Marti 61% gross, AITX 71%) offset by compressions (FB Financial NIM -4 bps QoQ). Capital allocation leans bullish with dividend hikes (Franklin +3% YoY, Farmer Mac +7%), Teleflex's $1B buyback from $1.8B divest proceeds, and MarketWise affirming $300M FY2026 billings/$1.80/share div. 20+ 13F-HR filings show persistent institutional overweight in tech/ETFs (Apple/NVDA top holdings across 15+ filers), implying conviction in mega-caps. Insider activity sparse but delinquent reports at F&M Bank flag minor concerns; forward-looking catalysts cluster around AGMs and Q1 earnings (e.g., MarketWise May 7). Overall, portfolio-level trends favor growth in niche consumer plays (golf, retail) but caution on energy/mobility volatility, with actionable buybacks/divs enhancing shareholder returns now.

20 high priority 30 medium 50 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — April 13, 2026

Across 50 filings in the USA S&P 500 Healthcare stream (though many span financials, industrials, and biotechs), overarching themes include robust capital raises via PIPEs, convertible notes, and offerings (e.g., Pineapple $53M financing, Newton $1.35M notes, Dare $17.35M units), offsetting revenue pressures in 7/15 companies with financials (avg revenue decline -20% YoY where reported, like New Fortress -36.2%, Lexaria -88.5%). Period-over-period trends show mixed results: loan/deposit growth in banks (FB Financial +28% YoY loans), margin compression (Digital Ally 23% to 10%, FB NIM 3.98% to 3.94% QoQ), and biotech positives (IDEAYA PFS 6.9 vs 3.1 months). Institutional 13F-HR filings (20/50) reveal heavy tech concentration (Apple/Nvidia top in 15+ portfolios, avg $50M+ positions), signaling conviction in megacaps amid volatility. Critical developments: IDEAYA's Phase 2/3 success flags H2 2026 NDA catalyst; capital allocation favors buybacks (Civeo 17% shares) and dividends (Franklin +3% YoY). Portfolio-level patterns highlight small-cap financing resilience but operational losses (avg net loss improvement in 4/8 loss-makers), with healthcare biotechs outperforming on trials/IP (IDEAYA, Catalyst Crew). Market implications: Opportunities in biotech catalysts and undervalued raises, risks in quorum failures and cyber incidents.

12 high priority 38 medium 50 total filings
· daily

US Executive Compensation Proxy SEC Filings — April 13, 2026

Across 30 DEF 14A proxy statements, a dominant theme is robust corporate governance with director elections, auditor ratifications, and say-on-pay votes clustered in May-June 2026 annual meetings, reflecting heightened shareholder scrutiny on executive compensation amid 2025 performance recaps. Period-over-period trends show strong outperformers like Farmer Mac (116% ROE, +7% YoY dividend), Civeo (Australian revenues $460M or 72% total, +10% YoY Adj EBITDA), and Bancorp (assets +8% to $9.4B, net income +4.6% to $228M, ROE +2pts to 29%), contrasted by delisting risks and reverse splits in small caps like Lunai Bioworks and BioRestorative Therapies. Capital allocation favors buybacks (Teleflex $1B from $1.8B divestiture proceeds, Civeo 2.3M shares for $54M or 17% outstanding) and dividend growth, signaling management conviction in financial health. Healthcare/biotech filings (Teleflex, Kyverna, Amphastar) exhibit positive sentiment with forward catalysts like H1 2026 BLA filing and H2 2026 deal closes, while financials show mixed ROA/ROE trends (e.g., Bancorp ROA -6.3%). Portfolio-level, 7/30 filings highlight M&A/portfolio shifts, 5/30 report leadership transitions, and 4/30 flag Nasdaq compliance issues, implying sector rotation opportunities into high-ROE financials and biotech catalysts. Investor implications include monitoring say-on-pay support (e.g., Farmer Mac 99% in 2025) for governance risks and capital returns for yield plays.

30 high priority 30 total filings
· daily

US IPO Pipeline SEC S-1 Filings — April 13, 2026

The IPO Pipeline stream features four high-materiality filings on April 13, 2026, highlighting a surge in strategic sector IPOs and combinations: Tivic's biopharma pivot via licensed assets, a $350M defense-focused SPAC from General Catalyst, pre-revenue rare earths explorer Rare Earths Americas, and Rumble's S-4 for cloud/data center M&A post-$775M Tether infusion. Period-over-period trends show Tivic incurring $347k exit charges in 2025 (up from prior operations) with $20-50k more expected, while others lack revenue history underscoring pre-commercial risks; no YoY revenue growth but asset pivots signal portfolio-level shift to high-growth niches like biopharma, critical minerals, defense, and AI infrastructure. Critical developments include FDA Fast Track/Orphan designations for Tivic (bullish catalyst), high-grade TREO resources for REA (up to 30.98%), SPAC's 24-27 month combo window, and Rumble's exclusion of Bitcoin assets for focused cloud buildout. Market implications point to thematic investing in US national security and supply chain resilience, with mixed sentiments (2 positive, 1 mixed, 1 neutral) amid dilution risks and no broad margin/revenue trends due to early-stage profiles. Portfolio pattern: 3/4 filings pre-revenue with M&A/licensing as growth levers, prioritizing non-dilutive prior funding ($140M for Tivic assets).

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — April 13, 2026

Across 50 filings dated April 13, 2026, dominant themes include major M&A activity like Somnigroup's $2.5B all-stock acquisition of Leggett & Platt (yielding $11.2B combined sales, immediate EPS accretion), biotech IPO pursuits (Alamar Biosciences +195% YoY revenue to $74.2M, Kailera's Phase 3 obesity pipeline), and a wave of Indian insolvencies/open offers (AGS Transact CIRP, Reliance Home Finance CoC meeting, multiple open offers at 26% stakes). Period-over-period trends show polarized performance: revenue growth in 6/18 reporting companies averaging +85% YoY (e.g., Alamar 195%, EACO 17.7%), but margin compression in 5/18 (Digital Ally to 10% from 23%, ALT5 to 41% from 48%) and net losses widening in microcaps (ALT5 -$344k from -$7.5k). RBI filings highlight persistent liquidity deficits (₹5.54L Cr absorption, SDF heavy usage), signaling tight Indian money markets. Critical implications: M&A catalysts for industrials, delisting risks (Sow Good Nasdaq notice), leadership transitions (Conagra CEO change, AdvanSix CFO), with forward catalysts like Phase 3 readouts (Kailera 2028), LEG merger close YE2026. Portfolio pattern: Outliers in biotech/health (positive sentiment 7/10) vs distress in small caps/fintech (negative/mixed 8/12).

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — April 13, 2026

Across 23 filings, sentiment is predominantly mixed (17/23), reflecting resilient revenue growth in select manufacturers and distributors (e.g., Arts-Way +29% YoY sales, EACO +17.7%) offset by widespread declines in tech, biotech, and consumer sectors (avg revenue drop ~15% YoY in 10 companies including Kopin -21.9%, Biomerica -21.6% 9M). Margin compression is a portfolio-level trend, affecting 9/23 companies with average -150 bps YoY (e.g., Digital Ally to 10% from 23%, Wetouch 31.8% from 32.2%), driven by cost pressures and crypto losses (Pineapple -$23M FV loss). Balance sheets show bifurcation: 8 companies strengthened via financing/dilution (e.g., Pineapple assets x9 to $48.9M, CONX equity positive $55M), while 7 saw cash/inventory deterioration amid operating losses. Net losses narrowed in 10 firms (avg improvement ~30% YoY), but dilution is rampant (12/23 with shares up >10x in cases like Edgemode 7,679% increase). No dominant insider patterns noted, but customer concentration (Wetouch top customers, Elite 100% FedEx) and China risks (Wetouch, others) emerge as systemic vulnerabilities. Q4/Q1 improvements signal potential inflection (New Fortress Q4 rev +19% QoQ), positioning nimble operators for recovery amid economic volatility.

23 high priority 23 total filings
· daily

US SEC Trading Suspension Halt Orders — April 13, 2026

Two small-cap companies, VEEA Inc. and Twin Vee PowerCats (VEEE), disclosed critical Nasdaq listing compliance failures in their April 2026 8-K filings, highlighting a portfolio-level theme of micro-cap distress amid prolonged bid price and market value deficiencies. VEEA failed Minimum Bid Price ($1.00), MVPHS ($15M), and MVLS ($50M) requirements by the March 30, 2026 deadline but secured a transfer to Nasdaq Capital Market (effective April 9, 2026) and a second 180-day extension to September 28, 2026, yielding mixed sentiment; VEEE received a delisting notice with no remediation path disclosed, paired with dilutive share authorization increases, driving negative sentiment. No period-over-period financial trends, revenue growth, or margin data were reported, but compliance failures imply QoQ/YOY deterioration in stock price (below $1 for VEEA since Sept 2025) and market cap metrics. Capital allocation shows VEEE pursuing defensive governance (classified board, 60% removal threshold) and massive share authorization (500M common shares), signaling entrenchment amid distress. Market implications include heightened delisting risks, potential reverse splits, and trading halts, creating short opportunities while VEEA's extension offers limited near-term stability. Overall, 2/2 filings exhibit high materiality (9/10), underscoring regulatory pressure on Nasdaq micro-caps with no bullish portfolio trends evident.

2 high priority 2 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — April 13, 2026

The 31 filings in the USA Corporate Distress & Bankruptcy stream reveal a surge in liquidity-seeking actions amid compliance pressures, with 6 companies (ClearOne, Veea, Sow Good, Twin Vee, Wheeler, Trinseo) facing Nasdaq listing deficiencies or delistings based on recent 10-K equity shortfalls and bid price failures, signaling widespread balance sheet weakness. Debt restructurings dominate positively (10 filings including Marathon Petroleum $5B revolver, AdaptHealth $1.1B facility at lower spreads, MPLX $2.5B), extending maturities and boosting liquidity, though Trinseo's interest payment waivers highlight acute distress. Equity offerings and convertibles (Newton Golf $1.35M funded, Angel Studios $30M priced, ImageneBio $30M PIPE) provide near-term cash but risk dilution, while M&A like Somnigroup/Leggett $2.5B all-stock deal offers turnaround potential with $50M synergies. No broad YoY/QoQ revenue declines explicitly stated, but implied deterioration from equity drops below $2.5M-$15M thresholds and contract losses (Ameriguard 58% 2026 rev). Portfolio trend: Margin-neutral to compressed operations driving 4 lease terminations/cuts, but capital raises counterbalance; sector implication is heightened bankruptcy risk for microcaps vs investment-grade refinancings signaling resilience.

31 high priority 31 total filings
· daily

US Executive Officer Management Changes SEC — April 13, 2026

Across 23 SEC filings on USA executive and director changes dated April 13, 2026, the overriding theme is leadership optimization for growth, with 16 positive appointments/retainments (70%) outpacing 7 departures/resignations, including high-materiality CEO shifts at Conagra Brands (new CEO June 1) and TVA (separation). No explicit period-over-period financial declines reported in any filing; instead, stability is inferred from retention incentives like ProFrac's 287k PSUs to CEO/Exec Chair and Vistagen's options to all employees, contrasting with sector peers facing talent wars. Forward-looking data highlights catalysts such as ALX Oncology's evorpacept milestones in 12-18 months, Commvault's reaffirmed FY2026 guidance, and NET Power's financing expertise for 2.4GW portfolio. Insider activity via equity grants (e.g., CG Oncology $4M options/$1M PSUs to new CFO) signals management conviction, with no sales or pledges noted. Biotech/pharma dominates (9/23 filings) with net positive hires amid clinical pushes, while CFO turnover (8 companies) suggests finance-led transformations. Capital allocation tilts to LTIPs over dividends/buybacks, prioritizing retention; portfolio implication: overweight firms with smooth transitions for alpha in Q2-Q3 2026.

23 high priority 23 total filings
· daily

US Corporate Board Director Changes SEC Filings — April 13, 2026

Across 23 8-K filings from April 13, 2026, focused on USA boardroom changes, a net positive trend emerges with 14 positive sentiment events (board expansions, experienced hires) outpacing 3 negative (sudden resignations) and 6 neutral, signaling proactive leadership refreshes amid 2026 economic pressures. CFO turnover dominates with 9 changes/appointments (e.g., Net Power, AdvanSix, CG Oncology, Commvault, AeroVironment), often with interim bridges and retention incentives like $420K salaries + RSUs, reflecting stabilization efforts. Biotech/pharma sector leads with 7 filings (e.g., Solana CMO exit, ALX CDOO hire for 12-18 month catalysts), while consumer/food sees high-materiality CEO shifts (Conagra 10/10). No broad period-over-period financial declines reported; instead, equity plan expansions (Xenon +30.6% shares) and reaffirmed guidance (Commvault FY2026) indicate capital allocation toward talent retention over buybacks/dividends. Portfolio implication: overweight firms with growth-aligned hires (e.g., Webtoon restructuring for 160M MAUs); monitor CEO voids like TVA for succession risks. Overall, 70% of changes expand expertise in transformation/AI/power markets, positioning for outperformance vs. stagnant peers.

23 high priority 23 total filings